Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Overview - The company has experienced a positive year, with significant progress in both commercial and R&D aspects, particularly with the clinical trials of zanidatamab [1] Commercial Progress - The company has made notable advancements in driving business growth on the commercial side [1] R&D Developments - There has been progression in the clinical trials of zanidatamab, indicating ongoing commitment to research and development [1] Corporate Development - Recent announcements in corporate development suggest strategic moves that may enhance the company's market position [1]